Vertex (VRTX) update #17
Posted by intelledgement on Wed, 24 Sep 08
Vertex (VRTX) stock rocketed up 16% today after the company released new data on their ongoing phase 2 trials of their anti-hepatitis C drug candidate, telaprevir. According to published reports, the data indicated that a two-dose-per-day regimen of telaprevir was just as effective as the three-dose-per-day regimen (at a lower dosage) that had been exclusively used up to now.
This is important for two reasons: [a] it is easier for patients to take a drug twice a day than three times a day and [b] some prospective competitors to telaprevir are designed for twice- or once-a-day dosing, which in the event any of them prove as effective, would have given that drug a big advantage if telaprevir required thrice-a-day dosing.